Five‐year clinical follow‐up of a randomized comparison of a polymer‐free sirolimus‐eluting stent versus a polymer‐based paclitaxel‐eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 418-424

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glycosylated Hemoglobin Is a Predictor of Major Adverse Cardiac Events after Drug-Eluting Stent Implantation in Patients with Diabetes Mellitus

By  

Cardiology, Vol. 116, Iss. 1, 2010-05 ,pp. : 51-57

Karger

Access to resources Recommend Favorite

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. S1, 2015-03 ,pp. : 734-743

John Wiley & Sons Inc

Access to resources Recommend Favorite

First report of a novel polymer‐free dual‐drug eluting stent in de novo coronary artery disease: Results of the first in human BICARE trial

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 405-411

John Wiley & Sons Inc

Access to resources Recommend Favorite

First‐in‐Man Study of Dedicated Bifurcation Sirolimus‐eluting Stent: 12‐month Results of BiOSS LIM® Registry

By  

JOURNAL OF INTERVENTIONAL CARDIOLOGY, Vol. 28, Iss. 1, 2015-02 ,pp. : 51-60

John Wiley & Sons Inc

Access to resources Recommend Favorite